PBAC's latest decision on Teriflunomide: Not recommended (2016). Considered for Treatment of patients with relapsing-remitting multiple sclerosis (RRMS).
PBAC outcome
Not recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2012
Submissions
3
2012 → 2016
Eligible population
Patients with relapsing-remitting multiple sclerosis (RRMS).
Therapy area
Neurology
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
interferon β-1a and interferon β-1b
Economic model
Cost-minimisation
ICER note
Cost-minimisation basis; no ICER calculated.
Risk sharing
Risk-sharing arrangement in place — Risk Share Arrangement (RSA) with annual Commonwealth expenditure cap in place for teriflunomide.
Why PBAC said no
Reasons cited in the latest PSD: market for oral therapies for RRMS had not yet stabilised; utilisation of other oral therapies (fingolimod and DMF) was higher and the market for oral treatments was still growing
Submission history
2012: Not recommended
Jul 2013: Recommended with restriction · Authority Required